Spotlight On... Novartis nabs two key approvals for Cosentyx to widen its lead on psoriasis rivals; China's diabetes scourge could mean $23B to drugmakers; Biden urges faster approval for cancer combos; and more...

Novartis ($NVS) has been working hard to snap up additional approvals for Cosentyx before its Big Pharma rivals get their next-gen psoriasis contenders to market. And as of Friday, it's done just that in the U.S., where the FDA approved the med as a treatment for psoriatic arthritis and ankylosing spondylitis. With three approvals under its belt, the med could reach peak sales of between $4 billion and $5 billion, Novartis Pharma's global head of development, Vas Narasimhan, said over the summer. More from FiercePharma

> The diabetes boom in China represents a $23 billion opportunity for drugmakers such as Novo Nordisk ($NVO), Sanofi ($SNY) and Eli Lilly ($LLY). Report

> Vice President Joe Biden pledged to speed up approval of combination cancer therapies, partly by encouraging different drugmakers to test their pipeline products together. Report

> The Gavi global alliance for vaccines signed a $5 million commitment to buy a Merck-developed vaccine against the deadly Ebola virus; the deal will help take the U.S.-based drugmaker through late-stage trials and regulatory approval, the organization said. Report

> The Indian Patent Office rejected a compulsory license on AstraZeneca's ($AZN) diabetes drug Onglyza (saxagliptin), filed by Hyderabad-based drugmaker Lee Pharma. Report

And Finally... Drugmakers are increasingly turning to LinkedIn to engage with the public. Report

Suggested Articles

Leaked details about an ad campaign to quell coronavirus fears before the election raise "every red flag I could dream of," an ex-HHS official said.

The FDA approved GlaxoSmithKline's Nucala to treat hypereosinophilic syndrome, making it the first biologic approved for that disease.

There’s an emerging trend within the SMA community to pair treatments up in the hope that they may provide even better outcomes, one analyst notes.